Company Info
Phone(475) 230-2596
Year Established
1992
Ticker
AZN
Exchange
NASDAQ
Contacts
Marc DunoyerCEO
Sean Christie
CFO & CAO
Todd Spalding
General Counsel
Fred Chereau
Senior VP, Strategy & Business Development
Scott Weintraub
Senior VP, U.S. Commercial Operations
Ruth Diazaraque
VP, R&D
Company Description
Alexion, an AstraZeneca company, has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).